ライフサイエンスコーパス: prostatectomy

1 d pathologic specimens obtained from radical prostatectomy.

2 3 months following robotic-assisted radical prostatectomy.

3 n men with biochemical failure after radical prostatectomy.

4 r biochemical recurrence (BCR) after radical prostatectomy.

5 ship goals for sexual recovery after radical prostatectomy.

6 ive bone scintigraphy who were scheduled for prostatectomy.

7 y to best determine resection margins during prostatectomy.

8 n to metastasis in patients choosing radical prostatectomy.

9 dergone MP MR imaging and subsequent radical prostatectomy.

10 ng high-b-value DWI and DTI at 3.0 T, before prostatectomy.

11 500, 1000, 1500, and 2000 sec/mm(2)) before prostatectomy.

12 us (18)F-fluciclovine PET/MRI before radical prostatectomy.

13 ze the literature on men's experiences after prostatectomy.

14 otherapy for recurrent prostate cancer after prostatectomy.

15 went 3.0-T MR imaging shortly before radical prostatectomy.

16 static delineation of prostate cancer before prostatectomy.

17 long-term (oncological) outcomes of radical prostatectomy.

18 otherapy for recurrent prostate cancer after prostatectomy.

19 ents underwent an MR examination followed by prostatectomy.

20 en with localized disease undergoing radical prostatectomy.

21 median of 4 d (range, 0-47 d) before radical prostatectomy.

22 25-OH D and adverse pathology at the time of prostatectomy.

23 apy for prostate cancer treated with radical prostatectomy.

24 arter of patients who have undergone radical prostatectomy.

25 rt demonstrated adverse pathology at radical prostatectomy.

26 surveillance, radiation therapy, or radical prostatectomy.

27 ge radiation treatment after primary radical prostatectomy.

28 rected IFS analysis for patients who undergo prostatectomy.

29 ts with biochemical recurrence after radical prostatectomy.

30 erwent 3-T multiparametric MR imaging before prostatectomy.

31 ability to predict whole-gland pathology at prostatectomy.

32 structure and molecular content from tumors prostatectomy.

33 al recurrence in patients undergoing radical prostatectomy.

34 patients who are not candidates for radical prostatectomy.

35 ostate cancer patients who underwent radical prostatectomy.

36 ndorectal MR imaging before robotic-assisted prostatectomy.

37 associated with metastatic progression after prostatectomy.

38 g after image-guided radiotherapy or radical prostatectomy.

39 by biochemical recurrence in patients after prostatectomy.

40 ses, and/or PCa-specific death after radical prostatectomy.

41 difference, 23.2 [95% CI, 17.7-28.7]), than prostatectomy.

42 ical margins intraoperatively during radical prostatectomy.

43 should be the current standard after radical prostatectomy.

44 ation of adjuvant radiotherapy after radical prostatectomy.

45 PCa underwent PET/CT, PET/MRI and MRI before prostatectomy.

46 d biopsy), and 404 (19.2%) underwent radical prostatectomy.

47 maging guidance during nerve-sparing radical prostatectomy.

48 wed by robotic-assisted laparoscopic radical prostatectomy.

49 r, is linked to recurrence following radical prostatectomy.

50 ntrations have to be monitored after radical prostatectomy.

51 6% (62/172) for PSA recurrence after radical prostatectomy.

52 from 11 primary lymphadenectomies at radical prostatectomy.

53 reclassification between biopsy and radical prostatectomy.

54 nts with normal bone scintigraphy undergoing prostatectomy.

55 ) participants had pathologic EPE at radical prostatectomy.

56 normal bone scintigraphy results undergoing prostatectomy.

57 biochemical cancer recurrence after radical prostatectomy.

58 ility of these measures in men after radical prostatectomy.

59 ectomy (1.8% vs 3.9%; P < .001), and radical prostatectomy (1.0% vs 2.4%; P < .001).

60 antly account for 40% of patients undergoing prostatectomy, 12% choosing watchful waiting or active s

61 ts: 118 in the primary cohort (who underwent prostatectomy), 137 in the post-prostatectomy validation

62 ns were performed for 20 500 (67.6%) radical prostatectomies, 1405 (6.8%) total nephrectomies, 2759 (

63 [95% CI, 57.4%-58.4%]), followed by radical prostatectomy (19.1% [95% CI, 18.7%-19.5%]) and watchful

64 tween those with upgrading of GS from 6 post prostatectomy (2.43 +/- 0.98; n = 26) compared to those

65 ncluded 30345 patients who underwent radical prostatectomy; 20802, total nephrectomy; 8060, partial n

66 ary incontinence was associated with radical prostatectomy (33.6 [95% CI, 27.8-39.2]); acute worsenin

67 y 3 months for patients who received radical prostatectomy (36.2 [95% CI, 30.4-42.0]), external beam

68 e [AUC] 0.70 [95% CI 0.65-0.76]) and radical prostatectomy (4.0 [1.6-9.7]; p=0.0024; AUC 0.57 [0.52-0

69 ued active surveillance (27.5%), 469 radical prostatectomy (41.1%), 249 external beam radiotherapy (2

70 ase), of whom 1523 (59.7%) underwent radical prostatectomy, 598 (23.5%) EBRT, and 429 (16.8%) active

71 All patients proceeded to prostatectomy (7 with pelvic nodal dissection).

72 apy was used in fewer patients who underwent prostatectomy (a difference of 25.0 percentage points; 9

73 After prostatectomy, a histologic map of the prostate was reco

74 tal of 163 patients were evaluated, 110 with prostatectomy after multiparametric MR imaging and 53 wi

75 ed in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously tre

76 ifty-six prostate cancer patients (18 before prostatectomy and 38 with biochemical recurrence) who un

77 Of these, 34 (89%) had undergone radical prostatectomy and 4 (11%) had undergone radiation treatm

78 He has decided against prostatectomy and brachytherapy because of strong person

79 ecurrence (BCR) after robot-assisted radical prostatectomy and ePLND in prostate cancer patients, str

80 20 patients underwent robot-assisted radical prostatectomy and ePLND with or without SNB (184 and 736

81 F-DCFPyL) followed by robot-assisted radical prostatectomy and extended pelvic LN dissection (ePLND)

82 rmediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissec

83 All patients underwent subsequent radical prostatectomy and extended pelvic lymph node dissection.

84 necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recur

85 l prostate cancer both after curative-intent prostatectomy and in a watchful waiting setting, possibl

86 /CT scans were performed followed by radical prostatectomy and intraoperative CLI of the excised pros

87 cer and biochemical recurrence after radical prostatectomy and low PSA concentrations (<=2.0 ng/mL).

88 nd the Mayo Clinic (Rochester, MN, USA; post-prostatectomy and metastatic validation cohorts).

89 are (68)Ga-PSMA PET/CT findings with radical prostatectomy and pelvic lymph node dissection (PLND) hi

90 31 patients (mean age, 67.2 y) who underwent prostatectomy and preoperative PET were retrospectively

91 cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0.2 to 2.0 ng/

92 From initial searches with main keywords (prostatectomy and qualitative study), 642 abstracts were

93 Men treated with radical prostatectomy and radiation therapy had a significantly

94 een adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) le

95 n initial staging compared with pathology at prostatectomy and the PPV for lesions with pathologic co

96 ll of whom were scheduled to undergo radical prostatectomy and underwent preoperative 3-T multiparame

97 with high-risk prostate cancer who underwent prostatectomy and were treated at 3 different academic i

98 Exclusion criteria were prior prostatectomy and/or contraindication to 3-T MR imaging.

99 thods Men were prospectively recruited after prostatectomy and/or radiation therapy with rising prost

100 ancreatectomies, 2,607 proctectomies, 12,228 prostatectomies, and 10,151 pulmonary lobectomies.

101 localized prostate cancer preceding radical prostatectomy, and cohort B patients had metastatic cast

102 We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the tr

103 interval: 2.95-3.87) for minimally invasive prostatectomy, and HR: 1.84 (95% confidence interval: 1.

104 n therapy, in 1-6% of patients after radical prostatectomy, and in 5-9% following brachytherapy or cr

105 essential component of men's adaptation post-prostatectomy, and provide comprehensive and individuali

106 ed the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on

107 Ca) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibl

108 .99), respectively, using nodal pathology at prostatectomy as a gold standard.

109 ohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of

110 when available, whole-gland pathology after prostatectomy as the "gold standard." INTERVENTIONS: Pat

111 Radical prostatectomy, as a primary monotherapy, offers the pote

112 natomy approach, starting with nerve-sparing prostatectomy, assumes that quality-of-life outcomes are

113 31, 2014, 19 256 patients underwent radical prostatectomy at an NHS provider in England.

114 ts with prostate cancer treated with radical prostatectomy at one of four US academic centers between

115 We analyzed 471 men who underwent radical prostatectomy at our institution with known family histo

116 uspected prostate cancer followed by radical prostatectomy between April 2016 and July 2018.

117 s of any age were eligible if they underwent prostatectomy between Jan 1, 1996, and Dec 31, 2009 (at

118 ll patients in England who underwent radical prostatectomy between Jan 1, 2010, and Dec 31, 2014, acc

119 derwent 3-T MRI and robotic-assisted radical prostatectomy between June 2018 and January 2019 were pr

120 ospectively in men treated with ADT for post-prostatectomy biochemical failure and correlated genotyp

121 fect of being an established robotic radical prostatectomy centre at the start of 2010 on net gains o

122 For each radical prostatectomy centre we analysed the effect of hospital

123 Of the 65 radical prostatectomy centres open at the start of the study per

124 Radical prostatectomy centres that closed were more likely to be

125 , and Dec 31, 2011 (at the Mayo Clinic; post-prostatectomy cohort) and were treated with ADT for bioc

126 In the post-prostatectomy cohorts, patients of any age were eligible

127 the 404 men who underwent subsequent radical prostatectomy, combined biopsy was associated with the f

128 oin hernia repair was observed after radical prostatectomy compared with controls, and men who receiv

129 djusted mean sexual domain score for radical prostatectomy decreased more than for EBRT (mean differe

130 lysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (2

131 nwide Inpatient Sample who underwent radical prostatectomy during MIRP diffusion between January 1, 2

132 ed) and nerve-sparing robot-assisted radical prostatectomy, during which IFS analysis was used, and s

133 rade prostate epithelial tissue from radical prostatectomies, each with its immediately surrounding s

134 Treatment with radical prostatectomy, EBRT, or active surveillance was ascertai

135 llowing CNI and that ROCK-I can prevent post-prostatectomy ED.

136 h detection rates in early BCR after radical prostatectomy, especially among patients with low PSA va

137 ion treatment increases apoptosis in radical prostatectomy ex vivo explant samples.

138 and adverse effects associated with radical prostatectomy, external beam radiation therapy (EBRT), a

139 compare quality of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachythe

140 Treatment with radical prostatectomy, external beam radiotherapy, brachytherapy

141 in part affected by factors associated with prostatectomy findings but may be positively affected by

142 version 2 and were compared with whole-mount prostatectomy findings.

143 sitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels.

144 ients with biochemical failure after radical prostatectomy for prostate cancer (PCa).

145 rostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associati

146 optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain.

147 cancer among individuals who undergo radical prostatectomy for treatment is around 25%.

148 d with all other options, and men undergoing prostatectomy for unfavorable-risk disease reported wors

149 covery, these outcomes remained worse in the prostatectomy group than in the other groups throughout

150 3 vs 65.2, P < .001) than men in the radical prostatectomy group.

151 One man died after surgery in the radical-prostatectomy group.

152 ients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low

153 Of the three treatments, prostatectomy had the greatest negative effect on sexual

154 ished modalities of radiotherapy and radical prostatectomy has been explored in this context, and the

155 Patient-reported outcomes after radical prostatectomy have focused on erectile function.

156 nfidence interval: 3.70-4.21) for retropubic prostatectomy, HR: 3.37 (95% confidence interval: 2.95-3

157 arly salvage radiotherapy, following radical prostatectomy in men (age >=18 years) with intermediate-

158 recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific ant

159 In total, 190 men underwent radical prostatectomy in the cohort.

160 ely correlated with disease recurrence after prostatectomy, invite a deeper characterization of its r

161 ce risk of prostate cancer following radical prostatectomy is critical for determining whether the pa

162 early salvage radiotherapy following radical prostatectomy is more appropriate for men who present wi

163 Axonal injury due to prostatectomy leads to Wallerian degeneration of the cav

164 reated consecutively by laparoscopic radical prostatectomy (LRP) between July 2014 and January 2019 w

165 rtic aneurysm repair, colectomy, cystectomy, prostatectomy, lung resection, total knee arthroplasty,

166 (primary tumor or prostate bed after radical prostatectomy), lymph node metastases, and other metasta

167 with biochemical failure (BF) after radical prostatectomy may benefit from dose-intensified salvage

168 After prostatectomy, men experienced physical, psychological,

169 After prostatectomy (n = 106), the sensitivity of both tracers

170 Results: After prostatectomy (n = 106), the sensitivity of both tracers

171 ,407), hysterectomy (n = 26,639), or radical prostatectomy (n = 11,183).

172 r primary local therapies, including radical prostatectomy (n = 38), radiation (n = 27) or combinatio

173 r primary local therapies, including radical prostatectomy (n = 38), radiation (n = 27), or a combina

174 th favorable-risk disease and treatment with prostatectomy (n = 402) or EBRT with androgen deprivatio

175 BCR after primary definitive treatment with prostatectomy (n = 42) or radiotherapy (n = 30).

176 active surveillance (n = 363), nerve-sparing prostatectomy (n = 675), external beam radiation therapy

177 d patients with prostate cancer treated with prostatectomy only (n = 84) and men without prostate can

178 cer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were inclu

179 in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lo

180 en with localized prostate cancer to radical prostatectomy or observation.

181 ce of groin hernia repair seen after radical prostatectomy or radiation therapy for prostate cancer.

182 egardless of radical treatment type (radical prostatectomy or radical radiotherapy), increasing comor

183 dolent prostate cancer often opt for radical prostatectomy or radiotherapy treatment for their diseas

184 In patients with BCR (after prostatectomy or radiotherapy), the capacity of (18)F-JK

185 tment choices including active surveillance, prostatectomy or radiotherapy.

186 p to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment.

187 [95% CI, 0.37-0.53]; P < .001), and radical prostatectomy (OR, 0.39 [95% CI, 0.25-0.61]; P < .001).

188 rostatectomy (RALP) compared to open radical prostatectomy (ORP) for prostate cancer.

189 vels (P = 0.005), as well as PSA nadir after prostatectomy (P < 0.001).

190 defined as a PSA of more than 0.2 ng/mL for prostatectomy patients or PSA of more than 2.0 ng/mL for

191 compared with histology findings in radical prostatectomy patients undergoing PLND.

192 A cohort of radical prostatectomy patients was stratified into men with no f

193 ted with therapeutic dose RT plus ADT versus prostatectomy plus ADT during the same time interval dem

194 chieved in the surgical technique of radical prostatectomy, post-operative complications such as erec

195 wing 3 inclusion criteria: BCR after radical prostatectomy (pT2-pT4 pN0-pN1 cM0, postoperative radiot

196 s on adjuvant and salvage radiotherapy after prostatectomy, published in August 2013, are clear, thor

197 men who were initially managed with radical prostatectomy, radiation treatment, or both and were bei

198 inical stage) and by treatment type (radical prostatectomy, radical radiotherapy, androgen deprivatio

199 L) for biochemical progression after radical prostatectomy (RADICALS-RT).

200 5% of men underwent conservative management, prostatectomy, radiotherapy (RT), and androgen deprivati

201 ssociated with robotic-assisted laparoscopic prostatectomy (RALP) compared to open radical prostatect

202 es after robot-assisted laparoscopic radical prostatectomy [RARP]).

203 Radical prostatectomy reduces mortality among men with localized

204 However, men undergoing prostatectomy reported clinically meaningful worse incon

205 f 187 patients had undergone primary radical prostatectomy (RP) (79/187 had secondary radiotherapy),

206 >= 3, >= pT3a) in men who underwent radical prostatectomy (RP) after initial surveillance.

207 Radical prostatectomy (RP) alone is often inadequate in curing m

208 -specific antigen (PSA) levels after radical prostatectomy (RP) fail prostate fossa (PF) salvage radi

209 salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patien

210 with multiparametric MRI (mpMRI) and radical prostatectomy (RP) histopathology.

211 aterone and prednisone (ELAP) before radical prostatectomy (RP) in men with locally advanced prostate

212 ostoperative radiotherapy (RT) after radical prostatectomy (RP) is unclear.

213 rapy (LDR) alone, EBRT alone, and/or radical prostatectomy (RP) should be offered to eligible patient

214 specific antigen (PSA) failure after radical prostatectomy (RP) to triage those who will benefit from

215 (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) using composite validation.

216 for variation in prostate biopsy and radical prostatectomy (RP) volume.

217 specimens from 239 men who underwent radical prostatectomy (RP), and it was investigated if miR-615-3

218 th biochemical recurrence (BCR) post radical prostatectomy (RP), but its longer term prognostic / pre

219 h biochemical recurrence (BCR) after radical prostatectomy (RP), but its longer-term prognostic or pr

220 d biochemical outcomes after delayed radical prostatectomy (RP), using descriptive statistics, the Ka

221 ) of prostate cancer (PCa) following radical prostatectomy (RP).

222 f 187 patients had undergone primary radical prostatectomy (RP; 79/187 had secondary radiotherapy), 3

223 Here, we used prostatectomy samples in a tissue microarray format and

224 Additional investigation in human prostatectomy samples showed that increased eIF4E phosph

225 n data from formalin-fixed paraffin-embedded prostatectomy samples with median 10.3 years follow-up w

226 The expression of SLCO2B1 was examined in prostatectomy samples, and the impact of SLCO2B1 express

227 athologist delineated cancers on whole-mount prostatectomy sections and calculated their volume by us

228 c centres and ten (27%) closed their radical prostatectomy service during the study period.

229 and the likelihood of closing their radical prostatectomy service.

230 The digitized prostatectomy slides were annotated for cancer and nonca

231 The prostatectomy specimen served as the reference standard.

232 n-fixed paraffin-embedded first-line radical prostatectomy specimens (embedded in tissue microarrays

233 tandard and targeted biopsy cores as well as prostatectomy specimens (n = 10).

234 Naive radical prostatectomy specimens from 535 patients was used for t

235 ] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk patie

236 Recent studies on extensive series of prostatectomy specimens have shown that tumors originati

237 d subcellular detail, obtained in 24 radical prostatectomy specimens immediately after excision.

238 nge, 2.4-9.2) and correlative 3+ staining of prostatectomy specimens on PSMA immunohistochemistry.

239 e MRI and histopathology of the biopsies and prostatectomy specimens respectively.

240 comprising >1500 primary PC patient radical prostatectomy specimens reveals that CCN3 expression cor

241 athologic examination of whole-mount radical prostatectomy specimens was used as the reference standa

242 80 to 0.98), confirming previous findings in prostatectomy specimens.

243 , and high-risk prostate cancer from radical prostatectomy specimens.

244 tissue microarrays constructed from radical prostatectomy specimens.

245 (PCa), bone metastasis can occur years after prostatectomy, suggesting that bone may provide dormancy

246 Using this method, post-prostatectomy surveillance of prostate specific antigen

247 s high detection rates for BCR after radical prostatectomy that are comparable to or better than thos

248 orts between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher

249 After prostatectomy, the fresh whole prostate specimens were i

250 For prostatectomy, the risk ratios (95% CIs) for undergoing

251 tantial reduction in mortality after radical prostatectomy; the number needed to treat to prevent one

252 rostate cancer and were scheduled to undergo prostatectomy; they had Gleason scores of 7-10 and a mea

253 tudy focusing on the experience of men after prostatectomy), this meta-synthesis included 15 studies.

254 n this cohort of patients undergoing radical prostatectomy, those with first-degree relatives who die

255 thological grades between biopsy and radical prostatectomy, three hundred and thirty men treated cons

256 ocalized measurements of light scattering in prostatectomy tissue microarrays.

257 ferred for (68)Ga-PSMA PET/CT before radical prostatectomy to rule out metastasis.

258 low, but complication rates ranged from 10% (prostatectomy) to 56% (lobectomy).

259 udy of 221637 patients who underwent radical prostatectomy, total nephrectomy, partial nephrectomy, h

260 fluciclovine-targeted prostate biopsy in non-prostatectomy-treated patients correlates with focal upt

261 true positivity for local recurrence in non-prostatectomy-treated patients.

262 Eight males undergoing prostatectomy under general anesthesia were included.

263 ith biochemically recurrent PC after radical prostatectomy undergoing (18)F-PSMA-1007 PET/CT imaging.

264 After radical prostatectomy, upgrades to grade group 3 or higher on hi

265 ong the men who underwent subsequent radical prostatectomy, upgrading and downgrading of grade group

266 nerve (CN) network for nerve-sparing radical prostatectomy using near-infrared cyanine voltage-sensit

267 ho underwent prostatectomy), 137 in the post-prostatectomy validation cohort, and 188 in the metastat

268 fied detection rate of (18)F-JK-PSMA-7 after prostatectomy varied among 54.5% (6/11 patients; PSA < 0

269 The median age at radical prostatectomy was 62 years.

270 men with localized prostate cancer, radical prostatectomy was associated with a greater decrease in

271 However, radical prostatectomy was associated with a reduced risk of meta

272 Radical prostatectomy was associated with worse urinary incontin

273 avorable-risk prostate cancer, nerve-sparing prostatectomy was associated with worse urinary incontin

274 in 170 men with whole-gland pathology after prostatectomy was greater than that of standard biopsy o

275 rdized institutional protocol before radical prostatectomy was performed by using the same 1.5-T MRI

276 ic contrast material-enhanced imaging before prostatectomy was retrospectively reviewed.

277 s who underwent MP MR imaging before radical prostatectomy was retrospectively used.

278 Significantly more radical prostatectomies were performed in hospitals with robots

279 centers, 251 patients with BCR after radical prostatectomy were evaluated in a retrospective analysis

280 ic MR imaging of the prostate before radical prostatectomy were included in a prospective database af

281 -specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analys

282 tudy 1: 9 PCa patients scheduled for radical prostatectomy were included.

283 te-specific antigen recurrence after radical prostatectomy) were prospectively selected for this expl

284 emical recurrence localisation after radical prostatectomy, whereas European Association of Urology g

285 95% CI, 0.56-0.68]) when determining radical prostatectomy, while regional variation (OR, 0.57 [95% C

286 urvival in PCa patients treated with radical prostatectomy who develop biochemical failure during and

287 patients with noncastrate BCR after radical prostatectomy who underwent (18)F-rhPSMA-7 PET/CT at our

288 s malignant or benign after correlation with prostatectomy whole-mount specimens.

289 y biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients wit

290 gned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as

291 patient underwent a robotic-assisted radical prostatectomy with bilateral pelvic lymphadenectomy.

292 distant metastases in patients after radical prostatectomy with biochemical failure.

293 (99m)Tc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection.

294 15 years have shown increased use of radical prostatectomy with pelvic lymph node dissection for prim

295 rostate adenocarcinoma who underwent robotic prostatectomy with whole-mount preservation of the prost

296 with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherap

297 imaged with (18)F-DCFBC PET before scheduled prostatectomy, with 12 of these patients also undergoing

298 All patients had undergone initial prostatectomy, with additional radiation therapy in 19.3

299 derwent nerve-sparing robot-assisted radical prostatectomy without multiparametric MR imaging and IFS

300 MA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at a PSA level